AKT1 and non-small cell lung carcinoma: Similarly, administering a membrane cholesterol depletor, methyl-β-cyclodextrin (MβCD) to gefitinib resistant non-small cell lung cancer (NSCLC) cell lines resulted in a significant decrease in IC50 of gefitinib as a consequence of inhibition of epidermal growth factor receptor (EGFR) activity as well as the activity of downstream MAPK/ERK and PI3K/Akt signaling pathways (Chen et al., 2018).